Company news
Sinopep-allsino Bio Pharmaceutical Co., Ltd. Class A (SSE:688076) news
Sinopep-allsino Bio Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 16, 2026: "Jiangsu Sinopep-Allsino Biopharmaceutical Co.…
Press releases & updates
"Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd."Announcement on Shareholding Reduction Plan by Certain Shareholders
September 15, 2026
"Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificates for Vonoprazan Fumarate Tablets and Glucosamine Sulfate Capsules
August 25, 2026
"Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report and Q1 2026 Report
July 9, 2026
"Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd."Announcement on Vesting Results for the 3rd Vesting Period under the 2023 Restricted Stock Incentive Plan and the Listing of Shares
July 8, 2026
Announcement on Meeting Vesting Conditions in 3rd Vesting Period in Restricted Stock Incentive Plan 2023
June 26, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 4, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 26, 2026
Announcement on Controlling Shareholder and Actual Controller Renewing the Agreement of Persons Acting in Concert
May 20, 2026
Announcement on Using Idle Self-owned Funds for Entrusted Wealth Management
April 29, 2026
Announcement on Voluntary Disclosure of Earnings Preannouncement for Q1 2026
April 7, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Voluntary Disclosure of Passing GMP Compliance Inspection for Drugs
February 3, 2026
JIANGSU SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD.: Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 2, 2026
JIANGSU SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. Earnings Preannouncement for 2025
January 30, 2026
Announcement on Using Idle Raised Funds for Cash Management
January 16, 2026
Announcement on Progress in Signing a Major Daily Operation Contract
December 30, 2025
Announcement on Receiving the Decision of Administrative Penalty
December 17, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Atosiban Acetate Injection
December 9, 2025
Announcement on Voluntary Disclosure of Agomelatine Tablets Prospective Winning of the 11th National Centralized Drug Procurement
October 28, 2025
Report for Q3 2025
October 22, 2025
Announcement on Voluntary Disclosure of Earnings Preannouncement for Q3 2025
October 10, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 5, 2025
2025 Semi-annual Report
August 20, 2025
Announcement on Voluntary Disclosure of Passing cGMP Site Inspection for Drugs
August 5, 2025
Announcement on the Voluntary Disclosure of Receiving Drug Registration Certificates for Sequiretic Acetate Injection and Agomelatine Tablets
July 31, 2025
Announcement on Implementation of Other Risk Warnings and Trading Suspension
July 18, 2025
Announcement on Voluntary Disclosure of Earnings Preannouncement for 2025 Interim Results
July 3, 2025
Announcement on Adjusting Matters Related to the 2023 Restricted Stock Incentive Plan
June 26, 2025
Announcement on Voluntary Disclosure of Signing Strategic Cooperation Agreement
June 6, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 4, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Fluvoxamine Maleate Tablets
May 27, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 23, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
May 15, 2025
Announcement on Redemption Results of "Sinopep-Allsino Convertible Bonds" and Share Changes
April 25, 2025
The Last Indicative Announcement on the Implementation of Redemption and Delisting of "Sinopep-Allsino Convertible Bonds"
April 23, 2025
Special Report on Deposit and Use of Raised Funds in 2024
April 22, 2025
The 3rd Indicative Announcement on the Implementation of Redemption and Delisting of "Sinopep-Allsino Convertible Bonds"
April 21, 2025
The 2nd Indicative Announcement on the Implementation of Redemption and Delisting of "Sinopep-Allsino Convertible Bonds"
April 18, 2025
Announcement on Implementing Redemption and Delisting of "Sinopep-Allsino Convertible Bonds"
April 16, 2025
Announcement on Voluntary Disclosure of Strategic Cooperation
April 9, 2025
Announcement on Conversion Result of Convertible Bonds and Share Changes
April 2, 2025
Announcement on Voluntary Disclosure of Performance Forecast in the First Quarter of 2025
March 27, 2025
Indicative Announcement on "Sinopep-Allsino Convertible Bonds" Expected to Meet Redemption Conditions
March 26, 2025
Announcement on Voluntary Disclosure of Subsidiary Passing the U.S. FDA On-site Inspection
February 28, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Voluntary Disclosure of Passing GMP On-site Inspection for Drugs
February 10, 2025
Announcement on Voluntary Disclosure of Obtaining the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets
February 9, 2025
Annual Earnings Preannouncement for 2024
January 24, 2025
Announcement on Using Idle Raised Funds to Temporarily Supplement Current Capital
January 22, 2025
Announcement on Voluntary Disclosure of Drug GMP Compliance Inspection Passed by Dry Suspension and Granule Production Line in New Oral Solid Preparation Workshop
January 20, 2025